Apollomics (NASDAQ:APLM) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Apollomics (NASDAQ:APLM) from a sell rating to a hold rating in a research note issued to investors on Saturday morning.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Apollomics in a research report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

Apollomics Stock Performance

NASDAQ:APLM opened at $20.92 on Friday. The stock’s 50-day moving average is $18.10 and its 200-day moving average is $13.96. Apollomics has a 1-year low of $3.66 and a 1-year high of $42.12.

About Apollomics

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.